Management of non-alcoholic fatty liver disease in patients with sarcopenia

References

• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018 Jan;67(1):328–357.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the L. European association for the study of d, european association for the study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388–1402.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. consensus interferon study group. Hepatology. 1999 Sep;30(3):787–793.
   PubMed Web of Science ®Google Scholar
• Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007 Jul;46(1):37–47.
   PubMed Web of Science ®Google Scholar
• Hsu CS, Kao JH. Genomic variation-guided management in chronic hepatitis C. Expert Rev Gastroenterol Hepatol. 2012Aug;6(4):497–506.
   Google Scholar
• Kagansky N, Levy S, Keter D, et al. Non-alcoholic fatty liver disease–a common and benign finding in octogenarian patients. Liver Int. 2004 Dec;24(6):588–594.
   PubMed Web of Science ®Google Scholar
• Koehler EM, Schouten JN, Hansen BE, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the rotterdam study. J Hepatol. 2012 Dec;57(6):1305–1311.
   PubMed Web of Science ®Google Scholar
• Merli M, Giusto M, Gentili F, et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver Int. 2010 Feb;30(2):208–214.
   PubMed Web of Science ®Google Scholar
• Hsu CS, Liu CH, Liu CJ, et al. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol. 2009 Mar;104(3):598–604.
   PubMed Web of Science ®Google Scholar
• Bressler BL, Guindi M, Tomlinson G et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003 Sep;38(3):639–644.
   PubMed Web of Science ®Google Scholar
• Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int. 2008 Feb;28(2):271–277.
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Suzuki Y, et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol. 2005 Apr;75(4):550–558.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015 Aug;149(2):389–97 e10.
   PubMed Web of Science ®Google Scholar
• Hsu CS, Liu WL, Chao YC, et al. Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection. Hepatol Int. 2015 Apr;9(2):231–242.
   PubMed Web of Science ®Google Scholar
• Wong VW, Chitturi S, Wong GL, et al. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2016Sep; 11: 56–67
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: european consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010 Jul;39(4):412–423.
   PubMed Web of Science ®Google Scholar
• de Blasio F, Di Gregorio A, de Blasio F, et al. Malnutrition and sarcopenia assessment in patients with chronic obstructive pulmonary disease according to international diagnostic criteria, and evaluation of raw BIA variables. Respir Med. 2018;134:1–5.
   PubMed Web of Science ®Google Scholar
• Kim G, Kang SH, Kim MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. PLoS One. 2017;12(10):e0186990.
   PubMed Web of Science ®Google Scholar
• Rantanen T. Muscle strength, disability and mortality. Scand J Med Sci Sports. 2003 Feb;13(1):3–8.
   PubMed Web of Science ®Google Scholar
• Fernandez-Mincone T, Contreras-Briceno F, Espinosa-Ramirez M, et al. Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications. Expert Rev Gastroenterol Hepatol. 2020 Dec;14(12):1141–1157.
   PubMed Web of Science ®Google Scholar
• Correa-de-Araujo R, Addison O, Miljkovic I, et al. Myosteatosis in the context of skeletal muscle function deficit: an interdisciplinary workshop at the national institute on aging. Front Physiol. 2020;11:963.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Margioris AN. Sarcopenic obesity. Hormones (Athens). 2018 Sep;17(3):321–331.
   PubMedGoogle Scholar
• Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007 Jun;22(6):775–777.
   PubMed Web of Science ®Google Scholar
• Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 2008 Dec;34(6 Pt 2):634–637.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015 Apr;50(4):364–377.
   PubMed Web of Science ®Google Scholar
• Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020 Mar;21(3):300–307e2.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16–31.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Arima K, Okabe T, et al. Usefulness of chair stand time as a surrogate of gait speed in diagnosing sarcopenia. Geriatr Gerontol Int. 2017 Apr;17(4):659–661.
   PubMedGoogle Scholar
• Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006 Nov 11;368(9548):1681–1688.
   PubMed Web of Science ®Google Scholar
• Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol. 2005 Dec;20(12):1825–1832.
   PubMed Web of Science ®Google Scholar
• Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007 Jun;22(6):788–793.
   PubMed Web of Science ®Google Scholar
• Mohan V, Farooq S, Deepa M, et al. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract. 2009 Apr;84(1):84–91.
   PubMed Web of Science ®Google Scholar
• Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010 May;51(5):1593–1602.
   PubMed Web of Science ®Google Scholar
• Jamali R, Khonsari M, Merat S, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008 May 14;14(18):2867–2871.
   PubMed Web of Science ®Google Scholar
• Dassanayake AS, Kasturiratne A, Rajindrajith S, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol. 2009 Jul;24(7):1284–1288.
   PubMed Web of Science ®Google Scholar
• Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007 Dec 21;13(47):6419–6424.
   PubMed Web of Science ®Google Scholar
• Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 2006 Sep;40(8):745–752.
   PubMed Web of Science ®Google Scholar
• Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43(3):508–514. Sep;.
   PubMed Web of Science ®Google Scholar
• Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38(10):954–961.
   PubMed Web of Science ®Google Scholar
• Omagari K, Kadokawa Y, Masuda J, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol. 2002 Oct;17(10):1098–1105.
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005 Nov 15;143(10):722–728.
   PubMed Web of Science ®Google Scholar
• Wong VW, Hui AY, Tsang SW, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4(9):1154–1161. Sep;.
   PubMed Web of Science ®Google Scholar
• Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):138–143.
   PubMed Web of Science ®Google Scholar
• Jeong EH, Jun DW, Cho YK, et al. Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol. 2013 Sep;19(3):266–272.
   PubMedGoogle Scholar
• Lee JY, Kim KM, Lee SG, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol. 2007 Aug;47(2):239–244.
   PubMed Web of Science ®Google Scholar
• Goh SC, Ho EL, Goh KL. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hepatol Int. 2013 Jun;7(2):548–554.
   PubMed Web of Science ®Google Scholar
• Malik A, Cheah PL, Hilmi IN, et al. Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. J Dig Dis. 2007 Feb;8(1):58–64.
   PubMed Web of Science ®Google Scholar
• De Hewavisenthi SJ, Dassanayaka AS, De Silva HJ. Clinical, biochemical and histological characteristics of a sri lankan population of non-alcoholic steatohepatitis (NASH) patients. Ceylon Med J. 2005 Sep;50(3):113–116.
   PubMedGoogle Scholar
• Tsai CH, Li TC, Lin CC. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J. 2008 Sep;101(9):900–905.
   PubMed Web of Science ®Google Scholar
• Chow WC, Tai ES, Lian SC, et al. Significant non-alcoholic fatty liver disease is found in non-diabetic, pre-obese Chinese in Singapore. Singapore Med J. 2007 Aug;48(8):752–757.
   PubMedGoogle Scholar
• Lin YC, Chou SC, Huang PT, et al. Risk factors and predictors of non-alcoholic fatty liver disease in Taiwan. Ann Hepatol. 2011 Apr-Jun;10(2):125–132.
   PubMed Web of Science ®Google Scholar
• Goh GB, Kwan C, Lim SY, et al. Perceptions of non-alcoholic fatty liver disease - an Asian community-based study. Gastroenterol Rep (Oxf). 2016 May;4(2):131–135.
   PubMed Web of Science ®Google Scholar
• Al-hamoudi W, El-Sabbah M, Ali S, et al. Epidemiological, clinical, and biochemical characteristics of Saudi patients with nonalcoholic fatty liver disease: a hospital-based study. Ann Saudi Med. 2012 May-Jun;32(3):288–292.
   PubMed Web of Science ®Google Scholar
• Babusik P, Bilal M, Duris I. Nonalcoholic fatty liver disease of two ethnic groups in Kuwait: comparison of prevalence and risk factors. Med Princ Pract. 2012;21(1):56–62.
   PubMed Web of Science ®Google Scholar
• Elmakki E, Aqeely H, Bani I, et al. Nonalcoholic Fatty Liver Disease (NAFLD) in Saudi Patients with T2DM in jazan region: prevalence and associated factors British journal of medicine & medical research. 2015;5(7):872–879.
   Google Scholar
• Kladchareon N, Treeprasertsuk S, Mahachai V, et al. The prevalence of nonalcoholic steatohepatitis in thai patients with non-HBV, non-HCV chronic hepatitis. J Med Assoc Thai. 2004 Sep;87(Suppl 2):S29–34.
   PubMedGoogle Scholar
• Wei JL, Leung JC, Loong TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol. 2015Sep; 1109: 1306–1314 quiz 1315.
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Yeung DK, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015 Jan;62(1):182–189.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016 Jul;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Tung TH, Chang TH, Chiu WH, et al. Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: experience at a teaching hospital. BMC Res Note. s.4:315
   Google Scholar
• Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord. 2004 Jan;28(1):167–172.
   PubMed Web of Science ®Google Scholar
• Shafiee G, Keshtkar A, Soltani A, et al. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017;16:21.
   PubMed Web of Science ®Google Scholar
• Hsu CS, Kao JH. Sarcopenia and chronic liver diseases. Expert Rev Gastroenterol Hepatol. 2018Dec;12(12):1229–1244.
   PubMed Web of Science ®Google Scholar
• Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):253–259.
   PubMed Web of Science ®Google Scholar
• Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in new Mexico. Am J Epidemiol. 1998 Apr 15;147(8):755–763.
   PubMed Web of Science ®Google Scholar
• Morley JE, Baumgartner RN, Roubenoff R, et al. Sarcopenia. J Lab Clin Med. 2001 Apr;137(4):231–243.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018 Jul;24(7):908–922.
   PubMed Web of Science ®Google Scholar
• VanWagner LB, Rinella ME. Extrahepatic manifestations of nonalcoholic fatty liver disease. Curr Hepatol Rep. 2016 Jun;15(2):75–85.
   PubMedGoogle Scholar
• Bhanji RA, Narayanan P, Allen AM, et al. Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology. 2017;66(6):2055–2065.
   PubMedGoogle Scholar
• Peng TC. Role of sarcopenia in NAFLD: definition is crucially important. Hepatology 2018 Mar;31;68(2):788–789
   Web of Science ®Google Scholar
• Kashiwagi K, Takayama M, Fukuhara K, et al. A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity. Clin Nutr ESPEN. 2020;38:86–93.
   PubMed Web of Science ®Google Scholar
• Seko Y, Mizuno N, Okishio S, et al. Clinical and pathological features of sarcopenia-related indices in patients with non-alcoholic fatty liver disease. Hepatol Res. 2019 Jun;49(6):627–636.
   PubMed Web of Science ®Google Scholar
• Bhanji RA, Narayanan P, Moynagh MR, et al. Differing impact of sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver disease. Liver Transpl. 2019 Jan;25(1):14–24.
   PubMed Web of Science ®Google Scholar
• Rachakonda V, Wills R, DeLany JP, et al. Differential impact of weight loss on nonalcoholic fatty liver resolution in a north american cohort with obesity. Obesity (Silver Spring). 2017 Aug;25(8):1360–1368.
   PubMed Web of Science ®Google Scholar
• Debroy P, Lake JE, Malagoli A, et al. Relationship between grip strength and nonalcoholic fatty liver disease in men living with hiv referred to a metabolic clinic. J Frailty Aging. 2019;8(3):150–153.
   PubMed Web of Science ®Google Scholar
• Shida T, Akiyama K, Oh S, et al. Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease. J Gastroenterol. 2018 Apr;53(4):535–547.
   PubMed Web of Science ®Google Scholar
• Kwon Y, Jeong SJ. Relative skeletal muscle mass is an important factor in non-alcoholic fatty liver disease in non-obese children and adolescents. J Clin Med. 2020 Oct 19;9(10):10.
   Web of Science ®Google Scholar
• Gao F, Zheng KI, Zhu PW, et al. FNDC5 polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. Br J Nutr. 2020;17:1–12.
   Google Scholar
• Koo BK, Um SH, Seo DS, et al. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver Int. 2018 Apr;38(4):695–705.
   PubMed Web of Science ®Google Scholar
• Shi YX, Chen XY, Qiu HN, et al. Visceral fat area to appendicular muscle mass ratio as a predictor for nonalcoholic fatty liver disease independent of obesity. Scand J Gastroenterol. 2021 Mar;56(3):312–320.
   PubMed Web of Science ®Google Scholar
• Wang YM, Zhu KF, Zhou WJ, et al. Sarcopenia is associated with the presence of nonalcoholic fatty liver disease in zhejiang province, China: a cross-sectional observational study. BMC Geriatr. 2021 Jan 14;21(1):55.
   PubMed Web of Science ®Google Scholar
• Golabi P, Gerber L, Paik JM, et al. Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease. JHEP Rep. 2020 Dec;2(6):100171.
   PubMedGoogle Scholar
• Aby ES, Lee E, Saggi SS, et al. Pretransplant sarcopenia in patients with NASH cirrhosis does not impact rehospitalization or mortality. J Clin Gastroenterol. 2019 Oct;53(9):680–685.
   PubMed Web of Science ®Google Scholar
• Idriss R, Hasse J, Wu T, et al. Impact of prior bariatric surgery on perioperative liver transplant outcomes. Liver Transpl. 2019 Feb;25(2):217–227.
   PubMed Web of Science ®Google Scholar
• Xia MF, Chen LY, Wu L, et al. The PNPLA3 rs738409 CG variant influences the association between low skeletal muscle mass and NAFLD: the shanghai changfeng study. Aliment Pharmacol Ther. 2019 Sep;50(6):684–695.
   PubMed Web of Science ®Google Scholar
• Himoto T, Miyatake K, Maeba T, et al. Verification of the nutritional and dietary factors associated with skeletal muscle index in japanese patients with nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. 2020;2020:3576974.
   PubMed Web of Science ®Google Scholar
• Carias S, Castellanos AL, Vilchez V, et al. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. J Gastroenterol Hepatol. 2016 Mar;31(3):628–633.
   PubMed Web of Science ®Google Scholar
• Hsu CS, Kao JH. An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia. Expert Rev Gastroenterol Hepatol. 2017 Aug;11(8):759–772.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010 Aug;52(2):774–788.
   PubMed Web of Science ®Google Scholar
• Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012 Apr;142(4):711–725 e6.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017 Feb 28;15(1):45.
   PubMed Web of Science ®Google Scholar
• Hirsova P, Ibrahim SH, Gores GJ, et al. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res. 2016 Oct;57(10):1758–1770.
   PubMed Web of Science ®Google Scholar
• Mota M, Banini BA, Cazanave SC, et al. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016 Aug;65(8):1049–1061.
   PubMed Web of Science ®Google Scholar
• Jones TE, Stephenson KW, King JG, et al. Sarcopenia–mechanisms and treatments. J Geriatr Phys Ther. 2009;32(2):83–89.
   PubMed Web of Science ®Google Scholar
• Rong S, Wang L, Peng Z, et al. The mechanisms and treatments for sarcopenia: could exosomes be a perspective research strategy in the future? J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):348–365.
   PubMed Web of Science ®Google Scholar
• Church TS, Kuk JL, Ross R, et al. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology. 2006 Jun;130(7):2023–2030.
   PubMed Web of Science ®Google Scholar
• Petersen KF, Dufour S, Befroy D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005 Mar;54(3):603–608.
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012 Apr;55(4):885–904.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Mar 14;385(9972):956–965.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018 May;67(5):1754–1767.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019 Nov 30;394(10213):2012–2024.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020 Apr;158(5):1334–1345 e5.
   PubMed Web of Science ®Google Scholar
• Arai H, Wakabayashi H, Yoshimura Y, et al. Chapter 4 Treatment of sarcopenia. Geriatr Gerontol Int. 2018 May;18(Suppl 1):28–44.
   PubMedGoogle Scholar
• Kim HK, Suzuki T, Saito K, et al. Effects of exercise and amino acid supplementation on body composition and physical function in community-dwelling elderly Japanese sarcopenic women: a randomized controlled trial. J Am Geriatr Soc. 2012 Jan;60(1):16–23.
   PubMed Web of Science ®Google Scholar
• Hey P, Gow P, Testro AG, et al. Nutraceuticals for the treatment of sarcopenia in chronic liver disease. Clin Nutr ESPEN. 2021 Feb;41:13–22.
   PubMed Web of Science ®Google Scholar
• Yoshimura Y, Bise T, Shimazu S, et al. Effects of a leucine-enriched amino acid supplement on muscle mass, muscle strength, and physical function in post-stroke patients with sarcopenia: a randomized controlled trial. Nutrition. 2019;58:1–6.
   PubMed Web of Science ®Google Scholar
• Takeuchi I, Yoshimura Y, Shimazu S, et al. Effects of branched-chain amino acids and vitamin D supplementation on physical function, muscle mass and strength, and nutritional status in sarcopenic older adults undergoing hospital-based rehabilitation: a multicenter randomized controlled trial. Geriatr Gerontol Int. 2019Jan; 191: 12–17
   PubMed Web of Science ®Google Scholar
• Mori H, Tokuda Y. Effect of whey protein supplementation after resistance exercise on the muscle mass and physical function of healthy older women: a randomized controlled trial. Geriatr Gerontol Int. 2018Sep;18(9):1398–1404.
   PubMed Web of Science ®Google Scholar
• Zhu LY, Chan R, Kwok T, et al. Effects of exercise and nutrition supplementation in community-dwelling older Chinese people with sarcopenia: a randomized controlled trial. Age Ageing. 2019 Mar 1;48(2):220–228.
   PubMed Web of Science ®Google Scholar
• Yoshimura Y, Wakabayashi H, Yamada M, et al. Interventions for treating sarcopenia: a systematic review and meta-analysis of randomized controlled studies. J Am Med Dir Assoc. 2017 Jun 1;18(6):553 e1–553 e16.
   Web of Science ®Google Scholar
• Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153–161.
   PubMed Web of Science ®Google Scholar
• Rooks D, Roubenoff R. Development of pharmacotherapies for the treatment of Sarcopenia. J Frailty Aging. 2019;8(3):120–130.
   PubMed Web of Science ®Google Scholar
• Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020 Dec;14(6):889–919.
   PubMed Web of Science ®Google Scholar